- MediPharm Labs’ (TSX:LABS) subsidiary published a study on medical cannabis’ impacts on anxiety and depression in fibromyalgia patients
- This is the largest peer reviewed published study of its kind on fibromyalgia and cannabis, with more than 800 patient assessments
- 75 per cent of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores
- MediPharm opened trading at $0.08 per share
MediPharm Labs’ (TSX:LABS) subsidiary published a study on medical cannabis’ impacts on anxiety and depression in fibromyalgia patients.
The study, “Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series,” was published by Harvest Medicine in the peer-reviewed American Journal of Endocannabinoid Medicine.
This is the largest peer reviewed published study of its kind on fibromyalgia and cannabis, with more than 800 patient assessments.
Between baseline and follow-up appointments, 75 per cent of patients saw a significant decrease in their self-reported illness severity and the study reported reductions in depression and anxiety scores.
Anxiety scores were improved in 22 per cent of those patients reporting mild-moderate severity, and in 48 per cent of patients reporting severe anxiety.
The study data shows that medical cannabis could play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety.
MediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids that develops and manufactures pharma-grade cannabis concentrates, active pharmaceutical ingredients, and advanced derivative products.
MediPharm opened trading at $0.08 per share.
Join the discussion: Find out what everybody’s saying about this stock on MediPharm Labs’ Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.